Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403105 | 0.90 | GPR119 (0.51) | GPR119GPR183KCNH2ABCB1ABCC1 | |
| SCHEMBL2892011 | 0.89 | GPR119 (0.53) | GPR119GPR183KCNH2ABCB1ABCC1 | |
| SCHEMBL1834757 | 0.87 | GPR119 (0.50) | GPR119GPR183KCNH2 | |
| SCHEMBL2247183 | 0.86 | GPR119 (0.49) | GPR119GPR183KCNH2 | |
| SCHEMBL8066046 | 0.85 | GPR119 (0.53) | GPR119GPR183KCNH2ABCB1ABCC1 | |
| SCHEMBL13534599 | 0.84 | GPR119 (0.51) | GPR119GPR183KCNH2ABCB1ABCC1 | |
| SCHEMBL1713507 | 0.83 | GPR119 (0.46) | GPR119GPR183KCNH2ABCB1ABCC1 | |
| SCHEMBL149441 | 0.83 | GPR119 (0.54) | GPR119GPR183KCNH2ABCB1ABCC1 | |
| SCHEMBL3218225 | 0.83 | GPR119 (0.47) | GPR119GPR183KCNH2ABCB1ABCC1 | |
| SCHEMBL2371526 | 0.82 | GPR119 (0.61) | GPR119GPR183KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| EP-2318399-B1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110195994-A1 | Piperidinyl GPCR Agonists | PROSIDION LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110195994-A1 | Piperidinyl GPCR Agonists | PROSIDION LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110195994-A1 | Piperidinyl GPCR Agonists | PROSIDION LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2318399-A1 | PIPERIDINYL GPCR AGONISTS | Prosidion Limited (GB) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010004346-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195994-A1 | Piperidinyl GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885GPR183 44/4885KCNH2 1416/4885 |
| US-20110230507-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885GPR183 46/4885KCNH2 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.